Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Qual Life Res. 2011 Oct 1;21(6):975–981. doi: 10.1007/s11136-011-0012-7

Table 3.

Summary of difference in VAS Drug High score in studies ALO-01-07-205 and ALO-01-07-106

Group comparisons Mean difference in VAS Drug High score, mm* Lower 95% CI Upper 95% CI
Study ALO-01-07-205 (oral dosing)
 Placebo versus IRMS 75.2 63.62 86.78
 Placebo versus intact ALO-01 45.7 29.24 62.16
 Placebo versus crushed ALO-01 39.8 21.98 57.62
 Crushed versus intact ALO-01 5.6 −3.54 24.74
 IRMS versus intact ALO-01 29.8 16.27 43.33
 IRMS versus crushed ALO-01 35.4 20.24 50.56
Study ALO-01-07-106 (IV dosing)
 Placebo versus MS 85.20 79.33 91.07
 Placebo versus MS + NTX 29.80 17.73 41.87
 MS versus MS + NTX 55.40 41.98 68.82
*

VAS Drug High at Emax were the following: 29.8 mm for MS + NTX; 85.2 mm for MS alone; and 0.0 for placebo

ALO-01 extended-release morphine with sequestered naltrexone, CI confidence interval, IRMS immediate-release MS, MS morphine sulfate, NTX naltrexone, VAS visual analog scale